Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470365 · ClinicalTrials.gov registry record · Phase 1
3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01470365: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Fox Chase Cancer Center.
NCT01470365 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 24 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01470365, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of 3-dimensional conformal radiation therapy (CRT) or intensity-modulated radiation therapy (IMRT) in treating patients with recurrent tumors. Radiation therapy (RT) uses high energy x rays to kill tumor cells. Palliative radiation therapy may help patients with recurrent tumors live more comfortably.
Primary Outcome
Defined as the dose level closest to, but not over that which is predicted to result in a dose limiting toxicity (DLT) rate of 20%, the target toxicity rate. Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. A DLT is a grade \>= 4 acute or grade \>= 3 late toxicity of an organ system within the reirradiation field in the following categories: skin or subcutaneous tissues, gastrointestinal, hepatobiliary, nervous system, renal and
Conditions Studied
Interventions
- RADIATION intensity-modulated radiation therapy
- PROCEDURE quality-of-life assessment
- RADIATION 3-dimensional conformal radiation therapy
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-11-03 |
| Est. Completion | 2019-02-21 |
| Phase | Phase 1 |
What the finished NCT01470365 record still lists
NCT01470365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 3 interventions - of which intensity-modulated radiation therapy is the first listed.
NCT01470365 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01470365 about?
NCT01470365 is a clinical study titled "3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors". This phase I trial studies the side effects and best dose of 3-dimensional conformal radiation therapy (CRT) or intensity-modulated radiation therapy (IMRT) in treating patients with recurrent tumors. Radiation therapy (RT) uses high energy x rays to kill tumor cells. Palliative radiation therapy ma...
What is the current status of trial NCT01470365?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-11-03. Estimated completion is 2019-02-21.
What conditions does trial NCT01470365 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT01470365?
The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), quality-of-life assessment (PROCEDURE), 3-dimensional conformal radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01470365?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01470365 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01470365's enrollment target sits among peer trials
24 68th of 83 higher than 11 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI